THE PENNANT GROUP, INC. (PNTG) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.91%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.91% | Share-based compensation / revenue. Period ending 2026-06-30. $10.08M ÷ $1.10B × 100 ≈ 0.91% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 1.10B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 10.08M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 62.20M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.10B | $10.08M | $62.20M | (m) | (m) | 0.91% | (m) | (m) |
| 2026-03-31 | (m) | $1.02B | $9.31M | $56.54M | (m) | (m) | 0.91% | (m) | (m) |
| 2025-12-31 | (m) | $947.71M | $8.94M | $51.89M | (m) | (m) | 0.94% | (m) | (m) |
| 2025-09-30 | (m) | $847.27M | $9.14M | $43.65M | (m) | (m) | 1.08% | (m) | (m) |
| 2025-06-30 | (m) | $798.92M | $8.82M | $44.21M | (m) | (m) | 1.10% | (m) | (m) |
| 2025-03-31 | (m) | $748.17M | $8.49M | $42.24M | (m) | (m) | 1.13% | (m) | (m) |
| 2024-12-31 | (m) | $695.24M | $7.78M | $38.12M | (m) | (m) | 1.12% | (m) | (m) |
| 2024-09-30 | (m) | $652.30M | $6.78M | $36.45M | (m) | (m) | 1.04% | (m) | (m) |
| 2024-06-30 | (m) | $611.81M | $5.99M | $32.71M | (m) | (m) | 0.98% | (m) | (m) |
| 2024-03-31 | (m) | $575.34M | $5.44M | $29.41M | $6.31M | (m) | 0.95% | 4.66× | Reported |
| 2023-12-31 | (m) | $544.89M | $5.37M | $25.17M | $5.92M | (m) | 0.99% | 4.25× | Reported |
| 2023-09-30 | (m) | $523.60M | $5.02M | $23.99M | $5.66M | (m) | 0.96% | 4.24× | Reported |
| 2023-06-30 | (m) | $501.76M | $936.00K | $24.07M | $5.22M | (m) | 0.19% | 4.61× | Reported |
| 2023-03-31 | (m) | $485.80M | $2.01M | $14.69M | $4.59M | (m) | 0.41% | 3.20× | Reported |
| 2022-12-31 | (m) | $473.24M | $3.09M | $12.74M | $3.82M | (m) | 0.65% | 3.34× | Reported |
| 2022-09-30 | (m) | $460.34M | $4.63M | $4.17M | $3.10M | (m) | 1.01% | 1.34× | Reported |
| 2022-06-30 | (m) | $453.91M | $9.95M | $-1.28M | $2.56M | (m) | 2.19% | -0.50× | Reported |
| 2022-03-31 | (m) | $447.94M | $10.06M | $5.41M | $2.21M | (m) | 2.25% | 2.45× | Reported |
| 2021-12-31 | (m) | $439.69M | $10.04M | $4.70M | $1.94M | (m) | 2.28% | 2.42× | Reported |
| 2021-09-30 | (m) | $435.90M | $9.80M | $10.98M | $1.69M | (m) | 2.25% | 6.51× | Reported |
| 2021-06-30 | (m) | $422.37M | $9.34M | $13.75M | $1.37M | (m) | 2.21% | 10.06× | Reported |
| 2021-03-31 | (m) | $404.77M | $8.79M | $16.26M | $1.20M | (m) | 2.17% | 13.59× | Reported |
| 2020-12-31 | (m) | $390.95M | $8.34M | $18.92M | $1.24M | (m) | 2.13% | 15.27× | Reported |
| 2020-09-30 | (m) | $372.48M | $8.00M | $13.43M | (m) | (m) | 2.15% | (m) | (m) |
| 2020-06-30 | (m) | $362.48M | $6.17M | $10.88M | (m) | (m) | 1.70% | (m) | (m) |
| 2020-03-31 | (m) | $352.47M | $4.72M | $8.12M | (m) | (m) | 1.34% | (m) | (m) |
| 2019-12-31 | (m) | $338.53M | $3.38M | $5.67M | (m) | (m) | 1.00% | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $286.06M | $2.38M | $20.63M | (m) | (m) | 0.83% | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $250.99M | $2.30M | $15.40M | (m) | (m) | 0.92% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |